For adults with more aggressive glioblastoma, treated with concurrent temozolamide and radiation therapy, median survival is
about 14.6 months and two-year survival is 30%. However, a 2009 study reported that almost 10% of patients with glioblastoma may live
five years or longer.
read more >>